Literature DB >> 23865834

Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients.

Yoichi Tanaka1, Atsushi Manabe, Hisaya Nakadate, Kensuke Kondoh, Kozue Nakamura, Katsuyoshi Koh, Akira Kikuchi, Takako Komiyama.   

Abstract

Abstract The aim of this study was to investigate the influence of daily 6-mercaptopurine (6-MP) and low-dose weekly methotrexate (MTX) combination treatment and methylenetetrahydrofolate reductase (MTHFR) haplotypes on toxicity during maintenance therapy in Japanese childhood acute lymphoblastic leukemia (ALL). We retrospectively analyzed the MTHFR C677T and A1298C polymorphisms and influence of haplotypes on toxicity in 73 patients. Patients with the MTHFR 677TT and 677CT + 1298AC were associated with severe liver toxicity (p = 0.014, odds ratio [OR] = 3.82, 95% confidence interval [CI] = 1.27-11.46) and more rapid onset of liver toxicity (p = 0.010). Patients with MTHFR 677TT and 677CT + 1298AC were associated with lower frequency of 6-MP and MTX dose reduction due to leukopenia (p < 0.05). No difference was observed in average drug doses in the MTHFR genotypes. In conclusion, the MTHFR C677T and A1298C haplotypes might be useful for monitoring adverse effects in childhood ALL maintenance therapy in Japanese patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23865834     DOI: 10.3109/10428194.2013.825902

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.

Authors:  Yue Zhou; Li Wang; Xiao-Ying Zhai; Li Wen; Fang Tang; Fan Yang; Xi-Ting Liu; Lei Dong; Li-Juan Zhi; Hai-Yan Shi; Guo-Xiang Hao; Yi Zheng; Evelyne Jacqz-Aigrain; Tian-You Wang; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

Review 2.  Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.

Authors:  Rochelle R Maxwell; Peter D Cole
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

3.  NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD.

Authors:  Y Kakuta; T Naito; M Onodera; M Kuroha; T Kimura; H Shiga; K Endo; K Negoro; Y Kinouchi; T Shimosegawa
Journal:  Pharmacogenomics J       Date:  2015-06-16       Impact factor: 3.550

Review 4.  Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.

Authors:  Lin Mei; Evelena P Ontiveros; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Meir Wetzler
Journal:  Blood Rev       Date:  2015-01-10       Impact factor: 8.250

Review 5.  [Research advances in pharmacogenomics of mercaptopurine].

Authors:  Xiao-Xiao Chen; Shu-Hong Shen
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-09

Review 6.  Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?

Authors:  Sunitha Kodidela; Pradhan Suresh Chandra; Biswajit Dubashi
Journal:  Eur J Clin Pharmacol       Date:  2013-12-27       Impact factor: 2.953

Review 7.  The Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.

Authors:  Shoshana Rudin; Marcus Marable; R Stephanie Huang
Journal:  Genomics Proteomics Bioinformatics       Date:  2017-04-06       Impact factor: 7.691

Review 8.  MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy.

Authors:  Maitane Umerez; Ángela Gutierrez-Camino; Carmen Muñoz-Maldonado; Idoia Martin-Guerrero; Africa Garcia-Orad
Journal:  Pharmgenomics Pers Med       Date:  2017-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.